Onkologicky Ustav Sv Alzbety s.r.o.
- Address
- lock Available on a paid plan
Breast Cancer Innovations
The site is conducting studies focused on advanced and early-stage breast cancer, aiming to improve outcomes with novel endocrine and targeted combinations.
- Testing PI3K inhibition alongside HER2‑directed therapy
- Comparing CDK4/6 inhibitor regimens for hormone‑receptor positive disease
- Evaluating antibody‑drug conjugate sacituzumab govitecan in triple‑negative cases
These trials involve seven investigators at the Bratislava hospital, contributing to the European oncology network.
Prostate Cancer Trials
Research at Onkologicky Ustav Sv Alzbety includes studies of metastatic castration‑resistant prostate cancer, seeking safer and more effective treatment options.
- Assessing a novel oral agent combined with enzalutamide
- Exploring safety of the agent as monotherapy in advanced disease
The investigations are part of a broader effort to expand therapeutic choices for men with advanced prostate tumors.
Colorectal Cancer and BRAF‑Driven Tumors
Trials target BRAF V600E‑mutant metastatic colorectal cancer, evaluating targeted combinations to overcome resistance.
- Comparing encorafenib plus cetuximab with or without chemotherapy
- Studying safety of a multi‑kinase inhibitor across solid tumors
Findings aim to refine precision medicine strategies for patients with this genetic alteration.
Broad Solid Tumor Targeted Studies
A series of early‑phase investigations examine a new selective inhibitor in various cancers, including NSCLC, liposarcoma, and tumors with CDK4/CCND1 amplification.
- Determining maximum tolerated dose and recommended phase 2 dose
- Evaluating drug‑drug interactions with standard endocrine agents
- Assessing food effect on pharmacokinetics
The research supports the development of versatile therapies that may benefit multiple tumor types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Pfizer Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.5trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkologicky Ustav Sv Alzbety s.r.o.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa | GBG Forschungs GmbH | Phase II | Recruiting | Dec 2022 | — |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fulvestrant | 4 | Unknown | 2021-11-29 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.